Cashing in on the Voucher Market: Two Small Cap Biotechs Bid for Attention

The priority review voucher program is already having an impact: some start-up companies are incorporating a voucher play into their bid to attract investors or acquirers.

"VioQuest could be among the first companies to receive a priority review voucher," says Michael Becker, CEO of the New Jersey based biopharma company VioQuest Pharmaceuticals Inc.

The company plans to submit an NDA for sodium stibogluconate (Lenocta) at the end of 2008 or early in 2009...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet